Venus Remedies Earns Prestigious REO Certification from CII for Second Consecutive Year

▴ Venus Remedies Limited
As the first pharmaceutical company in India to be honored with the REO certification from CII, Venus Remedies stands at the forefront of responsible and sustainable export practices. The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII).

Chandigarh, October 20, 2023: Venus Remedies is thrilled to announce that it has once again achieved the highly coveted Responsible Export Organisation (REO) certification from the Confederation of Indian Industry (CII). This achievement marks the second consecutive year that Venus Remedies has been recognized with this prestigious certification, reinforcing the company's unwavering commitment to excellence in the pharmaceutical industry.

 

As the first pharmaceutical company in India to be honored with the REO certification from CII, Venus Remedies stands at the forefront of responsible and sustainable export practices. This recognition comes after a rigorous and comprehensive screening and assessment process, emphasizing the company's dedication to upholding the highest standards of quality and integrity.

 

The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII) to companies that demonstrate exceptional commitment to responsible and sustainable export practices, ensuring high standards of quality, ethics, and integrity in their international business operations.

 

Mr. Peeyush Jain, Deputy Managing Director at Venus Remedies, expressed his gratitude for this remarkable achievement, stating, "The REO certification from the CII will enable us to expand our presence in our targeted 100 countries. The certification confirms our commitment to enhancing the lives of our members, improving workplaces, and contributing to a better world through the application of quality tools, techniques, and systems. It also serves as an endorsement of our company's export capabilities and manufacturing processes."

 

The REO certification underscores Venus Remedies' dedication to responsible and ethical business practices, setting the company apart as a leader in the global pharmaceutical landscape. It reflects the rigorous evaluation and recognition of the organization's systems and procedures as exemplary within the industry.

 

"This certification will empower our company to continue its upward trajectory and solidify its position as an export industry leader," continued Mr. Peeyush Jain. "The CII team has assessed our systems and procedures and found them to be exemplary within the organization. This certification will further assist us in enhancing our performance and setting standards of excellence."

 

Venus Remedies remains committed to maintaining the highest standards in pharmaceutical manufacturing, quality control, and ethical exporting practices. “We are immensely proud of this accomplishment, and it is an outcome of our team's dedication and hard work. Achieving the REO certification for the second consecutive year highlights our resolute to make a positive impact in the pharmaceutical industry. We remain steadfast in our pursuit of excellence, driving innovation, and delivering high-quality healthcare solutions to communities worldwide,” Akshansh Chaudhary, Executive Director & Chief Technology Officer, Venus Remedies.

 

About Venus Remedies

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by European- GMP, WHO-GMP and Latin American GMP (INVIMA), among others. Ranked 107th in Asia and among the world’s 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 130 patents worldwide and having more than 125 registered trademarks and 25 copyrights for its innovative research products.

Tags : #venusremedies #REO #certification #CII #pharmaceutical #pharma #healthcare #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Doomscrolling at Midnight: How Indians Are Sacrificing Sleep for ScreensMarch 31, 2025
Essential Medicines Price Surge: Are Patients Paying the Price?March 31, 2025
Prioritize your health during the holy days of RamzanMarch 31, 2025
Tired of Stomach Cramps? These Simple Foods Can Heal Your GutMarch 31, 2025
Regional growth booming for startups in 2024 - QBO Innovation studyMarch 31, 2025
Is long-acting HIV treatment as good as taking daily pills?March 31, 2025
Right to safe abortion cannot be dislocated from human rightsMarch 28, 2025
Popeyes® Opens Third Store in Hyderabad at Inorbit MallMarch 28, 2025
Popeyes® Opens Third Store in Hyderabad at Inorbit MallMarch 28, 2025
10 New HIV Cases in 2 Months: Has Kerala’s Drug Problem Gone Too Far?March 28, 2025
Type 2 Diabetes Under Attack: The Unexpected Power of Wearable TechMarch 28, 2025
Research identifies causes of catastrophic floodingMarch 28, 2025
Why a Few Extra Inches Around Your Waist Could Cost You Your LifeMarch 28, 2025
Young IT Professional Answers Call To Be Stem Cell DonorMarch 28, 2025
5 Hidden Signs of Nutrient Deficiency You Shouldn’t IgnoreMarch 28, 2025
Cancer in a Glass? What Science Says About Your Favourite WineMarch 27, 2025
BluHeat by Nysh.in Launches Innovative Cough Decongestion PatchesMarch 27, 2025
Jindal IVF plans to expand its presence in Himachal Pradesh and UPMarch 27, 2025
PartySmart Becomes India’s Go-To ‘Anti-Hangover Partner’ Across the Biggest Cultural FestivalsMarch 27, 2025
March 27, 2025